Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cells (Wuhan Sian Medical Technology)
- Development stage
- Unknown
- Lead developer
- Wuhan Si'an Medical Technology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Anti-CD19 CAR-T cells (Wuhan Sian Medical Technology) is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target the CD19 antigen, a protein expressed on the surface of most B-cell lineage cells. Developed by Wuhan Sian Medical Technology Co., Ltd., this therapy involves the genetic modification of a patient's own T cells to express a CAR that recognizes CD19, enabling the immune system to specifically identify and eliminate malignant B cells. It is primarily being investigated for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) and B-cell lymphoma. A notable clinical focus for this specific product is its use in patients with minimal residual disease (MRD) positivity, often evaluated in the context of hematopoietic stem cell transplantation (HSCT) to improve long-term outcomes and reduce relapse rates.
- Other names
- anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsCD19-targeted CAR-T cellsCD-19-targeted CAR-T cellsCD 19-targeted CAR-T cellsWuhan Sian CD19 CAR-T
02
Targets
Beyond the preview
Go deeper on anti-CD19 CAR-T cells (Wuhan Sian Medical Technology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cells (Wuhan Sian Medical Technology).